Walden Biosciences Announces Presentation at Canaccord Genuity 42nd Annual Growth Conference
04 Aug 2022
Walden Biosciences Announces Presentation at Canaccord Genuity 42nd Annual Growth Conference
Presentation to highlight transformational approach to treating kidney diseases
CAMBRIDGE, Mass., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Walden Biosciences, Inc. (Walden), a private, venture-backed biotechnology company focused on transforming the treatment of kidney disease, today announced that Blaine McKee, Ph.D., President and Chief Executive Officer of Walden Biosciences, will be participating in the CG 42nd Annual Growth Conference in Boston from August 8-11, 2022. Dr. McKee will deliver a corporate presentation on August 11, 2022 at 9:30 a.m. Eastern time.
About Walden Biosciences
Walden Biosciences is focused on developing breakthrough medicines to reverse the progression of both rare and common forms of kidney disease. Founded by world-renowned renal experts, the Company is applying a novel, multi-disciplinary approach that directly targets the kidneys to prevent damage and restore kidney function. Walden has active programs that address two novel targets for therapeutic intervention: soluble urokinase plasminogen activating receptor (suPAR) and dynamin. Targeting both suPAR and dynamin may be therapeutically useful in numerous types of renal diseases. Walden was launched in late 2020 with a $51 million Series A round of financing led by Arch Venture Partners with participation from other leading venture capital firms. For more information, please visit www.waldenbiosciences.com.
Investor Contact:
Stern Investor Relations
Anne Marie Fields
Managing Director
annemarie.fields@sternir.com
Media Contacts
Robert Stanislaro
Robert.Stanislaro@fticonsulting.com
-OR-
Helen O’Gorman
Helen.O’Gorman@fticonsulting.com
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Indications
Targets
Drugs
-Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.